1,720,986 research outputs found

    EFFETTI DELL’AMINOFILLINA SUL RITORNO DELLA COSCIENZA, TEMPO DI BURST SUPPRESSION E CONCENTRAZIONE STIMATA DI PROPOFOL DURANTE L'ANESTESIA TOTALE ENDOVENOSA CON INFUSIONE CONTROLLATA A TARGET: UNO STUDIO OSSERVAZIONALE SU 54 PAZIENTI

    No full text
    Aminophylline reverses the effects of propofol, and shortens the recovery time from general anesthesia by increasing the neuronal excitability. However, the aminophylline effects during total intravenous anesthesia (TIVA) with target-controlled infusion (TCI) have not been described yet. We compared: (a) the timing from (i) the end of propofol infusion until the return of eye-opening (REO) and the timing from (ii) the end of propofol infusion until the return of responsiveness (RoR) with or without an aminophylline bolus (4 mg kg-1) administered at the end of surgery, and (b) the timing from (iii) the start to the end of a Burst Suppression (BSupp) episode with or without an aminophylline bolus (4 mg kg-1) administered at BSupp emergence. Bispectral Index (BIS) values and the propofol effect-site concentration (CeP) delivered with TIVA-TCI at the 3 time points were also considered. This prospective observational study was approved by the Ethical Committee of Treviso Regional Hospital, Italy (N. 681/CE Marca), and registered with ClinicalTrials.gov (NCT06098196 for the RoR protocol and NCT06134037 for the BSupp protocol). All procedures in the study were in accordance with the ethical standards of our institutional and/or national research committees, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. We recruited 54 female patients scheduled for breast surgery with propofol (Eleveld PK/PD model) and remifentanil (Eleveld PK/PD model) TIVA-TCI. The patient assignment to deliver an aminophylline bolus was by chance, independently of patient scheduling, based on alternation between aminophylline users within the framework of a daily rotation 6-hour shift of the anesthesiologists involved in the study. The student-t test was used to compare continuous variables between the aminophylline and not-aminophylline groups. Categorical data were compared using a χ2 test. Statistical significance was set at p-values <0.05. Multivariate linear regression evaluating the demographic and treatment-effects on significant variables was also performed. 24 patients were enrolled for the RoR protocol. There were not statistically significant differences among demographic variables, CePs and BIS at Loss of Responsiveness (LoR) and at maintenance of anesthesia (MA), timing of anesthesia and total propofol dosage among the groups. Patients who received aminophylline bolus had lower timing for REO (8 [IQR 4-10] min vs 11 [IQR 10-13] min, p<0.05) and RoR (9 [IQR 6-10] min vs 11 [IQR 10-13] min, p<0.05). CeP REO (1.99 [1.84-2.66] μg ml-1 vs 1.50 [1.29-1.71] μg ml-1, p=0.001) and RoR (1.65 [1.52-2.25] μg ml-1 vs 1.40 [1.19-1.60] μg ml-1, p<0.05) in patients who received aminophylline were significantly higher. 30 patients were enrolled for the BSupp protocol. There were not statistically significant differences among demographic variables, CePs and BIS at LOR and at BSupp arousal, timing of anesthesia and total propofol dosage among the groups. Patients who received aminophylline bolus at BSupp detection, have significantly lower total timing of BSupp (116 [97.5-171.0] min vs 220 [193.5-267.0] min, p<0.01) and higher total % of Suppression Timing (32 [28-45]% vs 23 [20-26]%). Time from decreasing CeP to the time of ending of BSupp episode was significantly lower in patients treated with aminophylline (116 [97-168.5] min vs 158 [139-207.5] min, p < 0.05). Our results confirm the aminophylline effects in neuronal excitability during general anesthesia being useful not only in shortening awakening timing, but also in shortening BSupp episodes and decreasing anesthetic susceptibility, suggesting a potential neuroprotective role for cognitive disorders development

    Effect of Ketamine on the Bispectral Index, Spectral Edge Frequency, and Surgical Pleth Index During Propofol-Remifentanil Anesthesia: An Observational Prospective Trial

    Full text link
    Background: Ketamine administration during stable propofol anesthesia is known to be associated with an increase in bispectral index (BIS) but a "deepening" in the level of hypnosis. This study aimed to evaluate the association between the effect-site concentration of ketamine (CeK) and 2 electroencephalogram (EEG)-derived parameters, the BIS and spectral edge frequency (SEF95), after the administration of a ketamine bolus. Secondary aims included investigating the BIS and SEF95 variations with time and changes in the surgical pleth index (SPI). Methods: We conducted an observational, prospective, single-center study analyzing intraoperative data from 14 adult female patients undergoing breast oncologic surgery. During stable propofol-remifentanil target-controlled infusion (TCI) anesthesia, a ketamine analgesic bolus was delivered with the target CeK set to 1 μg.mL-1 (Domino model) corresponding to a dose of 0.57 mg.kg-1 (interquartile range [IQR] 0.56-0.57 mg.kg-1). Once the CeK reached a value of 1 μg.mL-1, the target CeK was set to 0 μg.mL-1. We determined the median BIS, SEF95, and SPI trends with time and as a function of the modeled CeK. Results: BIS and SEF95 showed no significant change from when ketamine was administered to when CeK=1 μg.mL-1, but a significant increase was observed at lower CeKs. The maximum BIS was reached at 16.0 minutes [10.2-22.7 minutes] after CeK=1 μg.mL-1, at CeK=0.22 μg.mL-1 [0.12-0.41 μg.mL-1]. The peak SEF95 value was observed at 10.0 minutes [8.62-14.1 minutes] after CeK=1 μg.mL-1, at CeK=0.43 μg.mL-1 [0.25-0.50 μg.mL-1]. No significant association was found between CeK and the registered SPI values. Conclusions: Our results show that BIS and SEF95, but not SPI, follow a CeK-dependent trend after administering a ketamine bolus. Interestingly, their peak values were not reached at CeK=1 μg.mL-1, but after several minutes after the drug infusion at CeKs in the 0.2 to 0.5 μg.mL-1 range. This may be explained by the specific pharmacodynamics of ketamine and its varying effects at different concentrations, as well as by the time delay associated with the calculation of the BIS
    corecore